Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014 (2014), Article ID 370368, 7 pages
Research Article

Inhibitory Effects of Edaravone in β-Amyloid-Induced Neurotoxicity in Rats

1Department of Neurology, Linyi People’s Hospital, Linyi City, Shandong 276000, China
2Department of Out-Patient, Yulin Teacher’s College Hospital, Yulin, Guangxi 537000, China
3Department of Neurology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangdong 510120, China

Received 16 January 2014; Accepted 24 February 2014; Published 2 April 2014

Academic Editor: Jin-Tai Yu

Copyright © 2014 Feng He et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Amyloid protein can damage nerve cells through a variety of biological mechanisms including oxidative stress, alterations in calcium homeostasis, and proapoptosis. Edaravone, a potent free radical scavenger possessing antioxidant effects, has been proved neuroprotective effect in stroke patients. The current study aimed to investigate the effects of EDA in an Aβ-induced rat model of AD, by studying Aβ1–40-induced voltage-gated calcium channel currents in hippocampal CA1 pyramidal neurons, learning and memory behavioral tests, the number of surviving cholinergic neurons in the basal forebrain, and the acetylcholine level in the hippocampus in this rat model of AD. The results showed that the Aβ1–40-induced increase of can be inhibited by EDA in a dose-dependent manner. Treatment with EDA significantly improved Aβ1–40-induced learning and memory performance. Choline acetyltransferase positive cells in basal forebrain and acetylcholine content in the hippocampus were increased by the administration of EDA as compared with the non-EDA treated Aβ1–40 group. These results demonstrate that EDA can inhibit the neurotoxic effect of Aβ toxicity. Collectively, these findings suggest that EDA may serve as a potential complemental treatment strategy for AD.

1. Introduction

Alzheimer’s disease (AD) is a neurodegenerative disease, whose pathogenesis is not fully understood. One factor known to promote the occurrence of AD is oxidative stress. Edaravone (EDA) is a free radical scavenger, which can reduce the damage caused by oxidative stress. In Japan, EDA has been widely used in the treatment of ischemic cerebrovascular disease since 2001. Recent experimental and clinical studies have revealed that EDA is also capable of producing neuroprotective effects in spinal cord infarction [1], multiple sclerosis [2], cerebral hemorrhage [3], aneurysms [4], brain injury [57], amyotrophic lateral sclerosis (ALS) [8, 9], and Parkinson’s disease [10, 11]. An effect of EDA in the treatment of AD has also been reported [12] and results from a small sample clinical trial showed improved cognitive performance and daily living activities in patients with mild-to-moderate AD in China.

Aβ, a neurotoxic substance, exerts complex biological effects. It damages nerve cells by oxidative stress, alters calcium homeostasis, and activates a variety of proapoptotic pathways, all of which play an important role in the pathogenesis of AD. Therefore, an important area of AD research involves that of identifying agents capable of inhibiting Aβ neurotoxicity. It has been reported that EDA reduced the oxidative damage caused by Aβ25–35 in PC12 cells, decreased apoptosis, and increased intracellular glutathione and superoxide dismutase concentrations [13]. Additional mechanisms through which EDA can reduce the generation of Aβ toxicity involve interfering with hydrolysis sites of the amyloid precursor protein (APP), increasing the activity of α-secretase, and reducing the hydrolysis of β-secretase upon APP [14]. Within our laboratory we showed that EDA inhibits Aβ1–40-induced VGCC current enhancement using a patch clamp technique [15]. In the present study, we expand upon these findings and apply EDA and Aβ1–40 together to observe the changes in VGCC currents of rat hippocampal pyramidal cells, as well as learning and memory responses in a rat model of AD, and assess survival of cholinergic neurons and levels of acetylcholine in specific brain areas. Therefore, this study provides important new data critical for understanding the neuroprotective effects and mechanisms of EDA against Aβ toxicity.

2. Material and Methods

All experiments were carried out in accordance with guidelines approved by ethical committee of Sun Yat-Sen University, which includes minimizing the number of animals used and their suffering.

2.1. Electrophysiology Experiments
2.1.1. Slice Preparation

Standard techniques were used to prepare 310 μm thick acute hippocampal slices from 14–21-day-old SD rats (provided by Guangdong Medical Laboratory Animal Center). Briefly, rats were anesthetized with sodium pentobarbital and decapitated. Brains were quickly removed and within 30 s placed into an ice-cold oxygenated artificial cerebral spinal fluid (ACSF) medium containing (in mmol/L) 126 NaCl, 3.5 KCl, 1.3 MgCl2, 2 CaCl2, 1.2 NaH2PO4, 25 NaHCO3, and 11 glucose. The ventromedial brain hemisphere was dissected to isolate and remove the rostral and caudal tips of the hippocampus. The brain tissue was mounted onto a block and transferred to the sectioning stage of a Vibratome (DTK-1000, DSK, Kyoto, Japan) filled with ice-cold ACSF such that the cutting stage and blade were completely submerged. The brain tissue was chopped into 310 μm thick sections and coronal slices were placed onto nylon mesh immersed in oxygenated ACSF at room temperature (23–25°C). Recordings were conducted after at least a 1 h recovery period and within approximately 6 h of duration of the preparation.

2.1.2. Electrophysiological Recordings

Slices were superfused at room temperature with oxygenated ACSF. Patch pipettes with a resistance of 4–7 MΩ when filled with the pipette solution were prepared from glass capillary tubes (B150-86-10, Sutter Company, USA) by a four-stage horizontal puller (MODEL P-97, USA). Slice patch clamp whole-cell recording experiments were performed at room temperature (23–25°C) using an EPC-10 amplifier (HEKA Company, Germany) driven by Pulse + Pulsefit software (HEKA Company, Germany). In voltage-clamp experiments, was elicited by depolarizing to +20 mV (100 ms) from a holding potential of −90 mV. The amplitude of was measured as the difference between the instantaneous current at the initial and maximal activating current values.

2.1.3. Solutions and Drugs

The pipette solution was composed of (in mmol/L) 120 potassium gluconate, 2 NaCl, 2 MgATP, 0.3 Na2GTP, 1 EGTA, and 10 HEPES. The pH was adjusted to 7.2–7.3 with KOH (1 mol/L), and osmolarity was adjusted to ~285 mOsm with KCl (2 mol/L). Aβ1–40 was stored as stock solutions (100 μmol/L) in H2O at −20°C and was maintained for at least 7 d at 37°C before use to allow the formation of fibril aggregation. Aβ1–40 was diluted in ACSF to a concentration of 1 μmol/L before use. EDA (MCI-186), purchased from BIOMOL, was dissolved in ACSF in concentrations of 1, 10, 100, and 300 μmol/L. CdCl2 were dissolved in ASCF with a final concentration of 150 μmol/L.

2.1.4. Data Analysis

Currents were normalized to membrane capacitance to calculate current densities (pA/pF). Cell membrane capacitance was determined online using the Pulse + Pulsefit software program. Graphics and statistical data analysis were performed using EXCEL 2007. Results are presented as means ± SEM. Statistical analysis was performed using paired t-tests and one-way ANOVA. A value of was required for results to be considered statistically significant.

2.2. AD Animal Models

Adult male SD rats (), weighing 250–300 g, were provided by the Experimental Animal Center at Sun Yat-Sen University. Rats were randomly divided into three groups consisting of sham, Aβ, and EDA-Aβ, with 16 rats in each group. To generate the AD animal model, Aβ1–40 was diluted to 1 μg/μL with sterile saline and incubated for one week at 37°C. Rats were anesthetized with 10% chloral hydrate (300 mg/kg) injected intraperitoneally. Rats were then fixed onto the stereotaxic apparatus, hair was cut, and skin was disinfected. A longitudinal incision was made along the midline to expose bregma. Microinjections were performed bilaterally into the hippocampus using the coordinates of AP-3.0 mm, L 2.0 mm, V 2.9 mm (bregma as the “zero point”). Condensed Aβ1–40 (10 μL) was bilaterally injected slowly into each hippocampus in the Aβ and Aβ-EDA groups. The same volume of saline was injected in the sham group. The injection time was 5 min and the needle was maintained at the injection site for 2 min before the needle was slowly withdrawn.

2.3. Drug Treatment

EDA was injected intraperitoneally in the Aβ-EDA group at a dose of 0.3 mg/kg, twice daily for 2 weeks. Saline was injected in the Aβ and the sham group, twice daily for 2 weeks.

2.4. Behavior Test

All rats were subjected to the Morris water maze test at five weeks after surgery. Testing was conducted over a 5-day period. The initial test procedures involved a navigation test, also known as acquired training. Rats were trained 4 times in the morning and 4 times in the afternoon each day with each training interval being 15–20 min. The quadrant designated for initial placement of the rat was randomly selected. Rats were placed in the water facing the wall. If the rat climbed onto the platform and remained a minimum of 3 seconds after swimming for some time, this was considered a successful trial and the time spent locating the platform (the escape latency) was recorded. If the rat failed to locate the platform within 120 s, it was directed to the platform where it was permitted to remain for a 10-second interval and an escape latency of 120 seconds was assigned. Escape latencies were recorded for each animal during this initial 5-day training period. The second phase of testing consisted of the space exploration test, also known as exploratory training. On the day following acquiring training, the platform was removed to conduct the exploratory training which lasted 120 s. The quadrant containing the original platform was considered the target quadrant. Rats were placed in the water facing the wall in the quadrant opposite to the target quadrant. The amount of time in the target quadrant and number of passes through the original platform location (piercing times) were recorded during the 120 s test period.

2.5. ChAT-Positive Cells in the Basal Forebrain Stained by Immunohistochemistry

Upon completion of behavioral testing, rats were perfused with 4% paraformaldehyde; the brain was removed and postfixed in the 4% paraformaldehyde for 6–12 hours at 4°C. The brains were maintained in sucrose solution 1 (50 g/L in PBS) for 8 h and in sucrose solution 2 (300 g/L in PBS) for 8 h. The basal forebrain was dissected, dehydrated, transparent, and embedded in the paraffin following the directions included in the kit. Coronal sections of 5 μm thickness were cut on a cryotome. Every fourth slice was collected for a total of 10 slices from each basal forebrain sample. ChAT immunohistochemistry was performed according to the directions provided in the kit. Three slices containing the medial septal nucleus (MS) and vertical arm nucleus of the diagonal band (VDB) were used for cell counting. The number of positive cells was counted within 5 randomly selected and nonoverlapping areas () of each slice. Cells that were not completely located within the field of view were not included in the total cell counts. The average number of cell counts from each animal was then used in the analysis.

2.6. ACh Content Analyzed by High Performance Liquid Chromatography (HPLC)

The hippocampus was quickly dissected on ice, weighed, and stored in the liquid nitrogen. Tissues were then transferred to an EP tube containing perchloric acid (0.1 mol/L, 1 mL/0.1 g of brain tissue) with 0.04% (w/v) and 0.04% (w/v) EDTA. Tissues were homogenized using an ultrasonic homogenizer for 20 s and centrifuged at 14,000 r/min × 20 min at 4°C. The supernatant was filtered through a 0.2 μm membrane and stored at −80°C for further analysis. The mobile phase was 0.2 mol/L Tris-maleate buffer (PH 7.0), containing TMACl 150 mg/L and OSA 10 mg/L. The flow rate was 1.3 mL/min. After separation with HPLC, the enzyme column (AChE 125U, ChO 75U) was used for postcolumn reaction, followed by electrochemical detection at 0.5 V.

2.7. Statistical Analysis

Data were expressed as mean ± SD. One-way ANOVA with the post hoc Q test or t-test was used for statistical analysis with the SPSS11.0 software program. was required for results to be considered statistically significant.

3. Results

3.1. Aβ1–40 Increased the Amplitude of   in Hippocampal CA1 Pyramidal Neurons

Bath application of Aβ1–40 at a concentration of 1 μmol/L increased the amplitude of by %; , , and this enhancement of was not reversed upon Aβ1–40 washout (Figure 1). CdCl2 (150 μmol/L in ACSF) blocked the inward current.

Figure 1: Effect of Aβ1–40 on in hippocampal neuron. (a) Increase in the amplitude of by Aβ1–40 (1 μmol/L) in hippocampal neurons. A, control; B, Aβ1–40 application; C, washout; D, CdCl2 (150 μmol/L) application. (b) Summary of data showing increases of current density ( (pA/pF)) by Aβ1–40. ** versus control.
3.2. EDA Reduced the Amplitude of Induced by Aβ1–40

Following the increase of by Aβ1–40, EDA was applied extracellularly at concentrations of 1, 10, 100, or 300 μmol/L. EDA reduced by %; , , %; , , %; , , and %; , , respectively (Figure 2). No differences in inhibiting increased by Aβ1–40 (, ) were obtained between the 100 and 300 μmol/L concentrations of EDA. No statistically significant differences were obtained among the different concentrations of EDA upon basal of hippocampal CA1 pyramidal neurons %; , , %; , , %; , , and %; , , respectively.

Figure 2: Inhibition of the action of Aβ1–40 by EDA in hippocampal neurons. (a) EDA reduced the amplitude of induced by Aβ1–40. a, Aβ1–40; B, EDA (100 μmol/L). (b) Summary of inhibition (percent) of by EDA at concentrations of 1, 10, 100, and 300 μmol/L. ** versus control.
3.3. Improved Learning and Memory Function in EDA-Treated Rats

As summarized in Table 1, rats in the Aβ group showed statistically increased latencies as compared to that in sham-operated rats (56.7 versus 20.5 s, ). The average latency for rats in the Aβ-EDA group was significantly decreased (38.1 s) as compared with the Aβ group but remained significantly increased when compared to the sham group (). In the space exploration test, rats in the sham group displayed the longest residence times in the target quadrant and the maximum piercings times while rats in the Aβ group demonstrated the shortest residence times in the target quadrant and the lowest number of piercings. These differences between the sham and Aβ groups were statistically significant (). The average residence times in the target quadrant, as well as the number of piercings for rats in the Aβ-EDA group, were significantly increased as compared with that of rats in the Aβ group ().

Table 1: Behavior test results of the rats in each group.
3.4. ChAT Staining in Basal Forebrain by Immunohistochemistry

Results from immunohistochemistry staining showed that fewer ChAT-positive cells were present in the basal forebrain of the Aβ group (Figure 3(b)). After EDA treatment, ChAT-positive cell numbers were significantly increased (Figure 3(c)). Rats in the sham group displayed the highest number of ChAT-positive cells (Figure 3(a)). Cell counts as performed under high power field showed that the mean + SD values of ChAT-positive cells in sham, Aβ, Aβ-EDA groups were 33.3 ± 7.7, 10.5 ± 5.7, and 25.4 ± 7.6, respectively (Figure 4). The differences among all three groups were statistically significant ().

Figure 3: Representative stains of ChAT-immunoreactive neurons of the rats in the three groups: (A) sham; (B) Aβ; (C) EDA. The toxic effects of Aβ resulted in a significant reduction in ChAT-positive cells (b). EDA treatment significantly restored ChAT-positive cell numbers (c), but this increase remained significantly lower than the cell counts in sham group (a).
Figure 4: Number of ChAT-immunoreactive neurons in the three groups. *, compared with Aβ; #, compared with sham.
3.5. Ach Content in Hippocampus

The highest content of Ach in the hippocampus was obtained in the sham group ( pmol/mg) and lowest in the Aβ group ( pmol/mg) (Figure 5). Ach content in the hippocampus of the Aβ-EDA group ( pmol/mg) was significantly increased as compared with that of the Aβ group () but remained significantly lower than that in the sham group ().

Figure 5: Content of Ach in the hippocampus in the three groups. *, compared with Aβ; #, compared with sham.

4. Discussion

Aβ, a neurotoxic substance, exerts complex biological effects. It damages nerve cells by oxidative stress, alters calcium homeostasis, and activates a variety of proapoptotic pathways, all of which play an important role in the pathogenesis of AD [12, 16]. Due to the high amount of oxygen consumption, high levels of unsaturated fatty acids, and the relative lack of antioxidant enzymes in the brain, nerve cells are particularly vulnerable to free radicals generated by oxidative stress, which results in lipid peroxidation and the damages membrane structure. It is known that Aβ deposition activates microglia and astrocytes, which release various anti-inflammatory cytokines and free radicals such as IL-α, S100β, and TNF-α. Aβ can promote the generation of reactive oxygen species (ROS), which play a critical role in oxidative damage to neurons. Aβ can also activate the complement system and promote the formation of immune complexes, which attack the neurons that are malnutritioned or damaged resulting in decomposition of the cell membrane and cell death. Moreover, Aβ can directly generate free radicals or bind with metal ions (Fe3+, Cu2+) to generate OH from H2O2 or other ROS via the Fenton reaction [17]. It has been reported that free radicals can cause increases in VGCC-mediated calcium currents [18, 19], which suggests that the free radicals generated by Aβ may be involved in this effect. Data from other studies indicate that Aβ may act directly on VGCC, which can temporally increase the inward calcium current [2022]. In the current study, Aβ1–40 was added to the perfusate, as a means to assess its acute effects on brain slices. With this approach, we found an instant increase in VGCC currents in hippocampal neurons, which is consistent with the findings of an earlier report by Chen et al. [20]. Of greater significance were our results demonstrating that acute EDA treatment effectively inhibited this Aβ effect in a concentration-dependent manner. Such results suggest that EDA administration can partially reverse Aβ effects upon current regulation, thereby reducing calcium influx and avoiding calcium overload. Such an effect may then represent one of the mechanisms underlying the therapeutic effects of EDA.

In our animal study, Aβ1–40 injected directly into the hippocampus resulted in a decrease in learning and memory function in the rats, thereby generating an AD animal model of AD. With EDA treatment of these AD rats, learning and memory scores were significantly improved. Immunostaining with ChAT revealed that cholinergic neuronal survival was higher in the basal forebrain and Ach concentration in the hippocampus was significantly higher in EDA-treated rats. These results suggest that EDA has the capacity of reducing the toxic effects of Aβ. Our findings are in accord with a number of other studies demonstrating a neuroprotective role for EDA. For example, EDA reduces Aβ expression [14], inhibits the production of inflammatory mediators leukotrienes, thus reducing the concentration of hydroxyl radical, decreases the production of the toxic carbonyl compound (carbonyl protein, advanced glycation end products, and malondialdehyde) [23], increases intracellular glutathione and superoxide dismutase concentrations [13], and reduces the expression of tau protein and glial fibrillary acidic protein (GFAP) in the cortex and hippocampus of the vascular dementia rat [24], thus reducing the highly phosphorylated tau protein concentrations [25]. In addition, EDA can stabilize the mitochondrial membrane potential, inhibit the mitochondrial-dependent apoptotic pathways, and inhibit the release of cytochrome C and the activation of Caspase-3 by reducing the Bax/Bcl-2 ratio [26]. Edaravone can also protect HT22 neurons from H2O2-induced apoptosis by inhibiting the MAPK signaling pathway moreover [27]. Taken together, the findings of these studies combined with the results of the current experiments suggest that EDA may serve as a neuroprotectant that may prove to be a particularly effective drug therapy for AD.

5. Conclusion

The present study demonstrated that edaravone, a free radical scavenger, could inhibit the neurotoxic effect of Aβ in rats and improve learning and memory ability of model animals through attenuation of Ca2+ overload, protecting cholinergic neurons in the basal forebrain, and increasing acetylcholine content in the hippocampus.

Conflict of Interests

The authors have no conflict of interests.


This study was supported by Grants to Jun Liu from the National Natural Science Foundation of China (no. 81372919 and no. 30970966) and the Guangdong Natural Science Foundation (no. S2013010013964).


  1. K. Suzuki, T. Kazui, H. Terada et al., “Experimental study on the protective effects of edaravone against ischemic spinal cord injury,” Journal of Thoracic and Cardiovascular Surgery, vol. 130, no. 6, pp. 1586–1892, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. J. A. Cohen, “Emerging therapies for relapsing multiple sclerosis,” Archives of Neurology, vol. 66, no. 7, pp. 821–828, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. T. Nakamura, Y. Kuroda, S. Yamashita et al., “Edaravone attenuates brain edema and neurologic deficits in a rat model of acute intracerebral hemorrhage,” Stroke, vol. 39, no. 2, pp. 463–469, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. T. Aoki, M. Nishimura, H. Kataoka, R. Ishibashi, K. Nozaki, and N. Hashimoto, “Reactive oxygen species modulate growth of cerebral aneurysms: a study using the free radical scavenger edaravone and p47phox-/- mice,” Laboratory Investigation, vol. 89, no. 7, pp. 730–741, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. T. Itoh, T. Satou, S. Nishida, M. Tsubaki, S. Hashimoto, and H. Ito, “The novel free radical scavenger, edaravone, increases neural stem cell number around the area of damage following rat traumatic brain injury,” Neurotoxicity Research, vol. 16, no. 4, pp. 378–389, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. T. Itoh, T. Satou, S. Nishida et al., “Edaravone protects against apoptotic neuronal cell death and improves cerebral function after traumatic brain injury in rats,” Neurochemical Research, vol. 35, no. 2, pp. 348–355, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. K. Dohi, K. Satoh, Y. Mihara et al., “Alkoxyl radical-scavenging activity of edaravone in patients with traumatic brain injury,” Journal of Neurotrauma, vol. 23, no. 11, pp. 1591–1599, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. H. Ito, R. Wate, J. Zhang et al., “Treatment with edaravone, initiated at symptom onset, slows motor decline and decreases SOD1 deposition in ALS mice,” Experimental Neurology, vol. 213, no. 2, pp. 448–455, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. H. Yoshino and A. Kimura, “Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis (phase II study),” Amyotrophic Lateral Sclerosis, vol. 7, no. 4, pp. 247–251, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. W. J. Yuan, T. Yasuhara, T. Shingo et al., “Neuroprotective effects of edaravone-administration on 6-OHDA-treated dopaminergic neurons,” BMC Neuroscience, vol. 9, article 75, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. N. Xiong, J. Xiong, G. Khare et al., “Edaravone guards dopamine neurons in a rotenone model for Parkinson's disease,” PLoS ONE, vol. 6, no. 6, Article ID e20677, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. C. Kaur and E.-A. Ling, “Antioxidants and neuroprotection in the adult and developing central nervous system,” Current Medicinal Chemistry, vol. 15, no. 29, pp. 3068–3080, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. G. L. Zhang, W. G. Zhang, Y. Du et al., “Edaravone ameliorates oxidative damage associated with Aβ25-35 treatment in PC12 cells,” Journal of Molecular Neuroscience, vol. 50, no. 3, pp. 494–503, 2013. View at Publisher · View at Google Scholar
  14. Y. E. Shen, Y. Wang, G. C. Yu, C. Liu, Z. Y. Zhang, and L. M. Zhang, “Effects of edaravone on amyloid-β precursor protein processing in SY5Y-APP695 cells,” Neurotoxicity Research, vol. 24, no. 2, pp. 139–147, 2013. View at Publisher · View at Google Scholar
  15. F. He, P. Luan, R. He et al., “Effect of Edaravone on Aβ1-40 induced enhancement of voltage-gated calcium channel current,” CNS Neuroscience & Therapeutics, vol. 18, no. 1, pp. 89–90, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. J. Everse and P. W. Coates, “Neurodegeneration and peroxidases,” Neurobiology of Aging, vol. 30, no. 7, pp. 1011–1025, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. T. Lynch, R. A. Cherny, and A. I. Bush, “Oxidative processes in Alzheimer's disease: the role of Aβ-metal interactions,” Experimental Gerontology, vol. 35, no. 4, pp. 445–451, 2000. View at Publisher · View at Google Scholar · View at Scopus
  18. T. Akaishi, K. Nakazawa, K. Sato, H. Saito, Y. Ohno, and Y. Ito, “Hydrogen peroxide modulates whole cell Ca2+ currents through L-type channels in cultured rat dentate granule cells,” Neuroscience Letters, vol. 356, no. 1, pp. 25–28, 2004. View at Publisher · View at Google Scholar · View at Scopus
  19. K. Hudasek, S. T. Brown, and I. M. Fearon, “H2O2 regulates recombinant Ca2+ channel α1C subunits but does not mediate their sensitivity to acute hypoxia,” Biochemical and Biophysical Research Communications, vol. 318, no. 1, pp. 135–141, 2004. View at Publisher · View at Google Scholar · View at Scopus
  20. L. Chen, C. J. Lui, M. Tang et al., “Action of β-amyloid peptide1-40 on IHVA and its modulation by ginkgolide B,” Acta Physiologica Sinica, vol. 58, no. 1, pp. 14–20, 2006. View at Google Scholar
  21. L.-M. He, L.-Y. Chen, X.-L. Lou, A.-L. Qu, Z. Zhou, and T. Xu, “Evaluation of β-amyloid peptide 25-35 on calcium homeostasis in cultured rat dorsal root ganglion neurons,” Brain Research, vol. 939, no. 1-2, pp. 65–75, 2002. View at Publisher · View at Google Scholar · View at Scopus
  22. R. M. Davidson, L. Shajenko, and T. S. Donta, “Amyloid beta-peptide (AβP) potentiates a nimodipine-sensitive L-type barium conductance in N1E-115 neuroblastoma cells,” Brain Research, vol. 643, no. 1-2, pp. 324–327, 1994. View at Google Scholar · View at Scopus
  23. M. Yu, S. Li, W. Leng, H. Chen, Y. Wu, and L. Yan, “Protective effects of MCI-186 on oxidative damage in a cell model of Alzheimer's disease,” Neural Regeneration Research, vol. 5, no. 16, pp. 1226–1230, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. J. H. Wang, L. D. Zhao, G. R. Jin, Y. Liu, and T. Shi, “Effects of Edaravone on the expressions of Aβ, Tau and GFAP to the brain of vascular dementia in rat,” Chinese Journal of Neuroanatomy, vol. 27, no. 2, pp. 203–208, 2011. View at Google Scholar
  25. S. Zhou, G. Yu, L. Chi et al., “Neuroprotective effects of edaravone on cognitive deficit, oxidative stress and tau hyperphosphorylation induced by intracerebroventricular streptozotocin in rats,” Neurotoxicology, vol. 38, pp. 136–145, 2013. View at Google Scholar
  26. Y. Yan, K. Gong, T. Ma et al., “Protective effect of edaravone against Alzheimer's disease-relevant insults in neuroblastoma N2a cells,” Neuroscience Letters, vol. 531, no. 2, pp. 160–165, 2012. View at Google Scholar
  27. Z. Y. Zhao, P. Luan, S. X. Huang et al., “Edaravone protects HT22 neurons from H2O2-induced apoptosis by inhibiting the MAPK signaling pathway,” CNS Neuroscience & Therapeutics, vol. 19, no. 3, pp. 163–169, 2013. View at Google Scholar